Erratum: Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer [Journal of International Medical Research, 41, 1, 48-54, 10.1177/0300060513475571];Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer

Journal of International Medical Research

Volumn 41, Issue 1, 2013, Pages 48-54

  Lin, Ying Li ^a   Ma, Jian Hua ^b   Luo, Xiang Li ^a   Guan, Tong Yu ^a   Li, Zhi Gang ^c  

^a Xuzhou Tumor Hospital (Xuzhou Third People's Hospital)   (China)

^b Chengde Central Hospital   (China)

^c General Hospital of Jilin Chemical Group Corporation (CNPC)   (China)

Author keywords

Bladder cancer; PCDH8; Prognosis; Promoter methylation; Protocadherin 8

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER EPITHELIUM; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DNA METHYLATION; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT IDENTIFICATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE CARE; PROGNOSIS; PROMOTER REGION; PROTOCADHERIN 8; SURVIVAL TIME; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

EID: 84878395801     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060514545432     Document Type: Erratum

References (27)

1. Kamat AM and Mathew P. Bladder cancer: imperatives for personalized medicine. Oncology (Williston Park) 2011; 25: 951-958, 960.
2. Jacobs BL, Lee CT and Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin 2010; 60: 244-272.
3. Morgan TM and Clark PE. Bladder cancer. Curr Opin Oncol 2010; 22: 242-249.
4. Kim WJ and Kim YJ. Epigenetics of bladder cancer. Methods Mol Biol 2012; 863: 111-118.
5. Hoffman AM and Cairns P. Epigenetics of kidney cancer and bladder cancer. Epigenomics 2011; 3: 19-34.
6. Enokida H and Nakagawa M. Epigenetics in bladder cancer. Int J Clin Oncol 2008; 13: 298-307.
7. Yu JS, Koujak S, Nagase S, et al. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene 2008; 27: 4657-4665.
8. Strehl S, Glatt K, Liu QM, et al. Characterization of two novel protocadherins (PCDH8 and PCDH9) localized on human chromosome 13 and mouse chromosome 14. Genomics 1998; 53: 81-89.
9. Kim SY, Yasuda S, Tanaka H, et al. Nonclustered protocadherin. Cell Adh Migr 2011; 5: 97-105.
10. Leshchenko VV, Kuo PY, Shaknovich R, et al. Genome-wide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 2010; 116: 1025-1034.
11. He D, Zeng Q, Ren G, et al. Protocadherin-8 is a functional tumor suppressor frequently inactivated by promoter methylation in nasopharyngeal carcinoma. Eur J Cancer Prev 2012; doi: 10.1097/ CEJ.0b013e328350b097.
12. Oosterlinck W, Lobel B, Jakse G, et al. for the European Association of Urology (EAU) Working Group on Oncological Urology. guidelines on bladder cancer. Eur Urol 2002; 41: 105-112.
13. Puri KS, Suresh KR, Gogtay NJ, et al. Declaration of Helsinki, 2008: implications for stakeholders in research. J Postgrad Med 2009; 55: 131-134.
14. Lin YL, Sun G, Liu XQ, et al. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma. J Int Med Res 2011; 39: 179-186.
15. Dehan P, Kustermans G, Guenin S, et al. DNA methylation and cancer diagnosis: new methods and applications. Expert Rev Mol Diagn 2009; 9: 651-657.
16. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-3229.
17. Lin YL, Liu XQ, Li WP, et al. Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma. Int Urol Nephrol 2012; 44: 111-117.
18. Draht MX, Riedl RR, Niessen H, et al. Promoter CpG island methylation markers in colorectal cancer: the road ahead. Epigenomics 2012; 4: 179-194.
19. Sandoval J and Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 2012; 22: 50-55.
20. Dumitrescu RG. Epigenetic markers of early tumor development. Methods Mol Biol 2012; 863: 3-14.
21. Morgan TM, Keegan KA and Clark PE. Bladder cancer. Curr Opin Oncol 2011; 23: 275-282.
22. Herr HW, Dotan Z, Donat SM, et al. Defining optimal therapy for muscle invasive bladder cancer. J Urol 2007; 177: 437-443.
23. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176: 2414-2422.
24. Van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009; 56: 430-442.
25. Frantzi M, Makridakis M and Vlahou A. Biomarkers for bladder cancer aggressiveness. Curr Opin Urol 2012; 22: 390-396.
26. Chang DW, Gu J and Wu X. Germline prognostic markers for urinary bladder cancer: obstacles and opportunities. Urol Oncol 2012; 30: 524-532.
27. Kandimalla R, van Tilborg AA, Kompier LC, et al. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. Eur Urol 2012; 61: 1245-1256.